AquaBounty Technologies (AQB)
(Delayed Data from NSDQ)
$1.07 USD
-0.03 (-2.73%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $1.06 -0.01 (-0.93%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.07 USD
-0.03 (-2.73%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $1.06 -0.01 (-0.93%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Zacks News
Will AquaBounty Technologies, Inc. (AQB) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues
by Zacks Equity Research
Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of -5.00% and -92.14%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Humana (HUM) Stock in Q2 Earnings?
by Zacks Equity Research
Humana's (HUM) second quarter is likely to gain traction from solid individual Medicare Advantage membership growth.